Summary
IT may be pure coincidence, but the purse strings appear to have loosened at AstraZeneca since the departure of Sir Tom McKillop, the austere Scotsman who quit the firm at the end of last year.
Stereotypes aside, there has been a marked change of emphasis at the Anglo-Swedish drugs giant in recent months.See the full content of this document
Extract
Cat Gives Booster to Astrazeneca ; City Focus
Having watched three potential blockbusters fail, David Brennan, the company's new American chief executive, has been buying in new promising medicines to fill gaping holes in the product pipeline.
The latest deal t...See the full content of this document
Sponsored links
